A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

Inclusion Criteria

• •Signed written informed consent must be obtained and documented according to International Conference on Harmonization (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior to study-specific screening procedures
• •A histologically or cytologically confirmed solid tumor that is advanced, metastatic, and/or inoperable following prior standard chemotherapy, and/or for which, in the opinion of the investigator, there is no alternative therapy, or for which monotherapy with erlotinib is appropriate
• •≥ 18 years of age
• •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)